Navigation Links
TPI Reports First Quarter Fiscal Year 2014 Financial Results
Date:11/15/2013

l industry. The Qionglai facility (QLF) post-relocation is approximately 18 miles from the Company's recently completed JCM facility. The proposed relocation project also includes our TCM pre-extraction plant which is currently located near the center of the city of Chengdu surrounded by a rapidly expanding residential area. Both the pre-extraction plant and the formulation plant will subsequently be relocated to Qionglai County to become a combined QLF plant, which is estimated to be 80 mu or approximately 13 acres. The combined QLF plant, designed and constructed according to the latest GMP standards, is expected to relieve the current capacity saturation at the current facilities. The re-location cost for Phase I (which includes relocation of both the formulation plant and pre-extraction plant) is estimated at $25 million, which, when completed, is expected to expand the current capacity by approximately 30%. If the Company decides to further expand the capacity, Phase II QLF, an additional $10 million may be invested to double the current capacity. Since the official start of the relocation project in February 2012, the construction of the QLF project has been progressing on schedule. The relocation of pre-extraction plant of Phase I is expected to be initiated by the end of 2013 calendar year which will be immediately followed by the initiation of the relocation of formulation plant.

Fiscal 2014 GuidanceThe Company continues experiencing restrictive pricing pressures in the healthcare market in China as a result of the enactment of additional healthcare reform policies. The prevailing tightened pricing control of generic medicines in China amid the healthcare reform and from the government's efforts to promote lower margined essential drugs (EDL) also simultaneously compressed our margins as well as our sale volumes of those generic products. These factors, together with the negative market environment of Azithromycin API pricing led to intensi
'/>"/>

SOURCE Tianyin Pharmaceutical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Nephros Reports Third Quarter 2013 Financial Results and Completes Bridge Financing
2. Vermillion Reports Third Quarter 2013 Results
3. Global Radiopharmaceutical Market 2012-2016 Reports
4. SPO Global Reports Results for Third Quarter 2013
5. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2014 Results; Teleconference and Webcast to be held on November 14, 2013
6. PTC Therapeutics Reports Third Quarter 2013 Financial and Corporate Results
7. EntreMed Reports Third Quarter 2013 Financial Results
8. Intercept Pharmaceuticals Reports Third Quarter 2013 Financial Results
9. Simcere Pharmaceutical Group Reports Preliminary Unaudited Third Quarter 2013 Results
10. Aratana Therapeutics Reports Third Quarter 2013 Financial Results
11. Regulus Reports Third Quarter 2013 Financial Results and Recent Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Investor-Edge has initiated coverage on the following equities: ... Company (NYSE: LLY ), Nektar Therapeutics (NASDAQ: ... Novartis AG (NYSE: NVS ). Free research on ... . On Friday, December 12, 2014, the NASDAQ Composite ... lost 1.79%, to finish the day at 17,280.83, and the ...
(Date:12/15/2014)... , Dec. 15, 2014  Stephen Squires, CEO and ... Quantum Materials Corp (OTCQB:QTMM), will be speaking at ... Materials (RCQM) on December 16th, 2014. The RCQM launch ... nanomaterials in attracting top faculty and students and by ... on research. "We have a long ...
(Date:12/15/2014)...  The Government of Ghana has endorsed ... (GBF) and Terumo BCT to respond to the emerging Ebola crisis ... long-term health system capacity to the citizens of Ghana ... Ebola Readiness and Resilience Initiative (GERRI) is a multi-agency effort designed ... the possible arrival of the Ebola epidemic , Provide new ...
Breaking Medicine Technology:Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 2Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 3Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 4Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 5Quantum Materials CEO Stephen Squires to Speak at Rice Center for Quantum Materials Launch 2Quantum Materials CEO Stephen Squires to Speak at Rice Center for Quantum Materials Launch 3Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 2Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 3Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 4Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 5Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 6
... , , , ... The rating agency Moody,s changed the outlook for ... , Moody,s gave as a ... the group,s business model. , , , ...
... INDIANAPOLIS , April 22 Today, WellPoint, Inc. (NYSE: ... article published this morning. , , ... Today,s Reuters story alleging that WellPoint employs a ... inaccurate and grossly misleading . The story incorrectly reports that WellPoint singles out ...
Cached Medicine Technology:Moody's Raised Outlook for Gerresheimer 2WellPoint's Reuters Response 2WellPoint's Reuters Response 3WellPoint's Reuters Response 4
(Date:12/17/2014)... By Kathleen Doheny ... -- Chronic sleep loss is rampant in America, and work ... "Work is the No. 1 sleep killer," said Dr. Mathias ... at the University of Pennsylvania Perelman School of Medicine. ... and older, found that work is the main activity exchanged ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 Main Street ... clinic, is weighing in on a new study providing ... on the oral hygiene of children. , Sufficient enough ... drinks, such as pop or juice drinks, with the ... looming, however, is whether drinks listed as 100% fruit ...
(Date:12/15/2014)... Health Dialog, a leading provider ... it has received Patient Oriented Accreditation from the ... Disease Management (DM) Programs for asthma, congestive heart ... disease and diabetes. This marks the 12th continuous ... Disease Management (DM) Programs, reaffirming Health Dialog’s focus ...
(Date:12/15/2014)... Kathy McAfee, America's Marketing Motivator, was announced ... the category of Best Blog 2014. McAfee received the ... career blog Networking Ahead which combines many ... their talent and influence through better networking, leadership and ... Networking Ahead for Business, has been motivating readers for ...
(Date:12/15/2014)... 15, 2014 Bacteroides is becoming the indicator ... it much more prevalent than coliforms, it cannot reproduce in ... environment. , Key Benefits of the new Bacteroides Sewage ... , Eliminates false positives from coliforms naturally occurring ... , Maintain the same sampling method with ...
Breaking Medicine News(10 mins):Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2Health News:Kathy McAfee, America’s Marketing Motivator, Wins Best Blog from Women World Awards 2
... N.J., Nov. 6 Osteotech, Inc.,(Nasdaq: OSTE ) ... to $25.7 million from third quarter 2006 revenue of ... 28% to $17.6 million for the three months ended ... from the same segments for the,third quarter of 2006. ...
... Thursday, November 8,2007, at 8:30 a.m. Eastern/2:30 p.m. Central ... CTIC and MTAX: CTIC),management team will host ... quarter achievements and financial results. Conference Call ... a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time ...
... SOUTH SAN FRANCISCO, Calif., Nov. 6 Rigel,Pharmaceuticals, Inc. (Nasdaq: ... and nine months ended September 30, 2007. For the ... $18.9,million, or $0.61 per share, compared to a net loss ... of 2006. Weighted average shares,outstanding for the third quarters of ...
... 6 - Elsevier Signs Agreement With ... major global healthcare company, Bayer,HealthCare AG, headquartered in ... Classic. Available in electronic format for,the first time, ... from 43 Excerpta Medica Abstract Journals published between ...
... TSX: COM, VANCOUVER, Nov. 5 /PRNewswire-FirstCall/ - Cardiome ... Bob Rieder, Chairman and,Chief Executive Officer, will present an ... Conference in New York at 1:20pm Eastern,Time (10:20am Pacific ... webcast of Mr. Rieder,s presentation can be accessed on,Cardiome,s ...
... StatSure Diagnostic,Systems, Inc. (OTC Bulletin Board: SSUR.OB) ... ("FDA"), through its Center for Devices and,Radiological Health, ... Amendments of 1988 ("CLIA") for an HIV 1/2 ... HIV 1/2 product,is marketed and distributed worldwide by ...
Cached Medicine News:Health News:Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09 2Health News:Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09 3Health News:Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09 4Health News:Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09 5Health News:Rigel Announces Third Quarter 2007 Financial Results 2Health News:Rigel Announces Third Quarter 2007 Financial Results 3Health News:Rigel Announces Third Quarter 2007 Financial Results 4Health News:EMBASE Classic Makes Inroads into Pharmaceutical Industry 2Health News:EMBASE Classic Makes Inroads into Pharmaceutical Industry 3Health News:Cardiome to Present at CIBC Conference 2Health News:Cardiome to Present at CIBC Conference 3Health News:StatSure's Patented HIV 'Barrel' Technology Receives CLIA Waiver From FDA 2Health News:StatSure's Patented HIV 'Barrel' Technology Receives CLIA Waiver From FDA 3
Curved shafts and tips with tying surfaces. Wide serrated handle with dull finish. Overall length 4.3 inches....
Curved shafts and tips with 7 mm tying platform. Serrated handle with polished finish. Overall length 4 inches....
Straight shafts with 5 mm tying platform. Wide handle with dull finish. Overall length 4.3 inches....
Straight shafts with 7 mm tying platform. Flat serrated handle with dull titanium finish. Overall length 4.5 inches....
Medicine Products: